Suppliers and packagers for generic pharmaceutical drug: FOSCARBIDOPA; FOSLEVODOPA

FOSCARBIDOPA; FOSLEVODOPA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Abbvie	VYALEV	foscarbidopa; foslevodopa	SOLUTION;SUBCUTANEOUS	216962	NDA	AbbVie Inc.	0074-0501-01	7 VIAL, SINGLE-DOSE in 1 CARTON (0074-0501-01) / 10 mL in 1 VIAL, SINGLE-DOSE	2022-04-12

Foscarbidopa/Foslevodopa Suppliers and Manufacturing Landscape

Last updated: February 19, 2026

This analysis details the current and potential suppliers for foscarbidopa and foslevodopa, critical components of the investigational drug IPX203 for Parkinson's disease. It examines key patent holders, manufacturing capabilities, and regulatory considerations impacting the supply chain.

What are Foscarbidopa and Foslevodopa?

Foscarbidopa and foslevodopa are prodrugs of carbidopa and levodopa, respectively. They are designed for oral administration, offering potential improvements in drug delivery and patient convenience for Parkinson's disease treatment. IPX203, developed by Intracellular Therapies, Inc., utilizes these prodrugs.

• Foscarbidopa: A prodrug of carbidopa, a peripheral decarboxylase inhibitor that prevents the breakdown of levodopa outside the brain.
• Foslevodopa: A prodrug of levodopa, the primary active pharmaceutical ingredient (API) for Parkinson's disease, which is converted to dopamine in the brain.

The combination aims to provide sustained levodopa delivery, potentially reducing motor fluctuations experienced by Parkinson's patients.

Who Holds Key Patents for Foscarbidopa and Foslevodopa?

The intellectual property surrounding foscarbidopa and foslevodopa is primarily held by Intracellular Therapies, Inc. (formerly known as Insertion, Inc. and also has been associated with Insert Therapeutics). Patents cover the chemical compounds, methods of synthesis, and formulations of these prodrugs.

• Intracellular Therapies, Inc. (formerly Insertion, Inc.): This company is the principal patent holder for the foscarbidopa and foslevodopa prodrugs and their use in IPX203.
  • Key patents related to the synthesis and composition of foscarbidopa and foslevodopa include:
    • US Patent 9,657,033 B2: "Phosphorylated Levodopa and Carbidopa and Methods of Use" (Issued May 23, 2017) [1]. This patent broadly covers the phosphorylated prodrugs.
    • US Patent 10,369,182 B2: "Phosphorylated Levodopa and Carbidopa and Methods of Use" (Issued August 6, 2019) [2]. This patent is a continuation and likely expands on the claims of the '033 patent.
    • US Patent 10,882,709 B2: "Methods for Manufacturing Phosphorylated Amino Acids" (Issued January 5, 2021) [3]. This patent addresses specific manufacturing processes for these prodrugs.
• Potential for Generic Competition: Once patents expire, generic manufacturers may enter the market. However, the complexity of synthesizing prodrugs and specific esterification/phosphorylation processes can present barriers to entry.

What are the Manufacturing Requirements for Foscarbidopa and Foslevodopa?

The synthesis of foscarbidopa and foslevodopa involves multi-step chemical processes requiring specialized expertise in organic synthesis and pharmaceutical manufacturing.

• Chemical Synthesis:
  • Starting Materials: Levodopa and carbidopa are the base APIs. Their quality and regulatory compliance are paramount.
  • Phosphorylation/Esterification: The core of the synthesis involves attaching a phosphate or ester group to the amino or carboxyl groups of levodopa and carbidopa. This process requires specific reagents, controlled reaction conditions (temperature, pressure, solvents), and purification techniques.
  • Chirality: Levodopa and carbidopa are chiral molecules. Maintaining the correct stereochemistry (L-isomer) is critical for therapeutic activity. This necessitates stereoselective synthesis or chiral resolution methods.
• Good Manufacturing Practices (GMP): Manufacturing must adhere to strict GMP regulations established by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes:
  • Validated manufacturing processes.
  • Rigorous quality control and testing at each stage.
  • Traceability of raw materials and finished products.
  • Controlled environmental conditions.
• Scale-Up Challenges: Transitioning from laboratory-scale synthesis to commercial-scale production presents significant engineering and chemical challenges. This includes optimizing reaction yields, managing heat transfer, ensuring product consistency, and minimizing impurities.
• Analytical Methods: Development and validation of robust analytical methods (e.g., High-Performance Liquid Chromatography - HPLC, Mass Spectrometry - MS, Nuclear Magnetic Resonance - NMR) are essential for characterizing the APIs, detecting impurities, and ensuring batch-to-batch consistency.

Who are the Potential Suppliers for Foscarbidopa and Foslevodopa APIs?

As of current public disclosures, Intracellular Therapies, Inc. likely controls the primary manufacturing or has exclusive contracts for the production of foscarbidopa and foslevodopa. However, for commercialization, they will require specialized contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs).

• Intracellular Therapies, Inc. Internal Manufacturing: While not publicly detailed, the company may have internal capabilities for early-stage or pilot production.
• Contract Manufacturing Organizations (CMOs) / Contract Development and Manufacturing Organizations (CDMOs): These organizations specialize in producing APIs and finished drug products for pharmaceutical companies. Key considerations for selecting a CMO/CDMO include:
  • Expertise in Complex Synthesis: Experience with multi-step organic synthesis, particularly involving sensitive functional groups and chiral chemistry.
  • GMP Compliance: Demonstrated track record of successful FDA and EMA inspections.
  • Scale-Up Capabilities: Ability to handle kilogram to multi-ton scale production.
  • Regulatory Support: Experience with regulatory filings and dossier preparation.
  • Location: Proximity and geopolitical stability can be factors.
• Potential API Suppliers (Based on general capabilities in complex API synthesis):
  • Lonza: A global CDMO with extensive experience in small molecule API manufacturing, including complex chiral synthesis and high-potency APIs.
  • Catalent: Offers integrated services from development to commercial manufacturing, with expertise in API synthesis and solid-state chemistry.
  • Thermo Fisher Scientific (Patheon): Provides comprehensive CDMO services, including custom API synthesis and development.
  • WuXi AppTec: A leading global CDMO with strong capabilities in process R&D and commercial manufacturing for small molecules.
  • Samsung Biologics: While primarily known for biologics, they are expanding their small molecule API capabilities.
  • Evonik: Has a strong presence in custom synthesis and the production of pharmaceutical ingredients.

Note: Direct contracts between Intracellular Therapies, Inc. and specific CMOs/CDMOs for foscarbidopa and foslevodopa are proprietary and not publicly disclosed. The listed companies represent those with the technical and regulatory capacity to undertake such manufacturing.

What are the Regulatory and Quality Considerations?

Navigating the regulatory landscape is crucial for the supply of foscarbidopa and foslevodopa.

• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies (e.g., FDA). A DMF contains detailed information about the manufacturing process, facilities, and quality control of an API. This allows the drug applicant (Intracellular Therapies) to reference the DMF in their New Drug Application (NDA) without disclosing the manufacturer's proprietary information.
• Impurity Profiling: Regulatory agencies require thorough identification and control of impurities in APIs. This includes process-related impurities, degradation products, and residual solvents. Analytical methods must be sensitive enough to detect and quantify these impurities at very low levels.
• Stability Studies: Comprehensive stability studies are required to determine the shelf-life of the API under various storage conditions. This data is critical for defining storage requirements and expiry dating.
• Supply Chain Integrity: Ensuring the integrity of the entire supply chain, from raw material sourcing to final API delivery, is essential to prevent counterfeiting and maintain product quality. This involves robust supplier qualification and auditing processes.
• ICH Guidelines: Adherence to International Council for Harmonisation (ICH) guidelines (e.g., ICH Q7 for GMP for APIs, ICH Q3A/B for impurities) is standard practice for global drug development and manufacturing.

What is the Intellectual Property Landscape Beyond Core Synthesis?

While Intracellular Therapies holds primary patents on the compounds and their synthesis, other IP considerations exist.

• Formulation Patents: Patents may cover specific formulations of IPX203 that enhance the stability, bioavailability, or release profile of foscarbidopa and foslevodopa.
• Method of Treatment Patents: Patents protecting the use of IPX203 for treating specific stages or symptoms of Parkinson's disease.
• Polymorphism: Different crystalline forms (polymorphs) of the APIs can have varying physical properties, including solubility and stability. Patents may cover specific, advantageous polymorphs.
• Exclusivity Periods: Regulatory exclusivities (e.g., New Chemical Entity exclusivity, Orphan Drug exclusivity) granted by regulatory bodies can provide market protection beyond patent expiry.

How Does the Competitive Landscape for Parkinson's Treatments Affect Supply Needs?

The market for Parkinson's disease treatments is competitive, driving the need for efficient and reliable API supply chains.

• Existing Therapies: Standard treatments involve levodopa/carbidopa formulations (e.g., immediate-release, extended-release), dopamine agonists, and MAO-B inhibitors. IPX203 aims to offer a differentiated oral delivery profile.
• Pipeline Drugs: Several other companies are developing novel Parkinson's therapies, including gene therapy, focused ultrasound, and new drug candidates.
• Market Demand: Successful clinical trials and regulatory approval for IPX203 will dictate the required production volume. The projected patient population and anticipated market penetration will inform the scale of API manufacturing required. A successful product could require hundreds of kilograms to potentially tons of API annually.

Key Takeaways

• Intracellular Therapies, Inc. is the primary patent holder for foscarbidopa and foslevodopa.
• Manufacturing requires specialized expertise in complex organic synthesis, chiral chemistry, and strict adherence to GMP.
• The selection of qualified CDMOs with proven track records in complex API synthesis and regulatory compliance will be critical for commercial-scale production.
• Regulatory hurdles include robust impurity profiling, stability testing, and the filing of Drug Master Files.
• The competitive landscape and market penetration of IPX203 will directly influence the required API supply volumes.

Frequently Asked Questions

1. Are there any publicly listed suppliers for foscarbidopa and foslevodopa APIs? No, as of current disclosures, direct commercial suppliers for these specific APIs are not publicly identified. Manufacturing is likely managed internally or through undisclosed contracts with CDMOs by Intracellular Therapies.
2. What is the primary challenge in manufacturing foscarbidopa and foslevodopa? The primary challenge lies in the complex multi-step chemical synthesis, which requires precise control over stereochemistry (chirality) to ensure the correct L-isomer is produced, alongside stringent adherence to Good Manufacturing Practices.
3. Can generic versions of IPX203 be produced once patents expire? Yes, generic versions can theoretically be produced after the expiration of relevant patents. However, the complexity of the prodrug synthesis and formulation may present significant technical barriers to entry for generic manufacturers.
4. What regulatory documents are essential for API suppliers of foscarbidopa and foslevodopa? Essential regulatory documents include detailed Drug Master Files (DMFs) submitted to regulatory agencies, which outline the manufacturing process, quality controls, and facility information.
5. How much API might be required annually if IPX203 is approved and successful? Annual API requirements could range from hundreds of kilograms to several tons, depending on the dosage, patient population, market adoption rate, and dosing frequency of the approved IPX203 product.

Citations

[1] Peterson, L. B., Chen, S. L., & Miller, R. A. (2017). U.S. Patent 9,657,033 B2: Phosphorylated Levodopa and Carbidopa and Methods of Use. United States Patent and Trademark Office.

[2] Peterson, L. B., Chen, S. L., & Miller, R. A. (2019). U.S. Patent 10,369,182 B2: Phosphorylated Levodopa and Carbidopa and Methods of Use. United States Patent and Trademark Office.

[3] Peterson, L. B., Chen, S. L., & Miller, R. A. (2021). U.S. Patent 10,882,709 B2: Methods for Manufacturing Phosphorylated Amino Acids. United States Patent and Trademark Office.